

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA BIOTECH SERVICES HOLDINGS LIMITED

中國生物科技服務控股有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock code: 8037)

GRANT OF SHARE OPTIONS SUPPLEMENTAL ANNOUNCEMENT

Reference is made to the announcement of China Biotech Services Holdings Limited (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) dated 6 January 2023 (the “**Announcement**”) in relation to the grant of Share Options to the Grantee, Ms. Chui Hoi Yam (“**Ms. Chui**”). Capitalised terms used in this announcement shall have the same meaning as defined in the Announcement unless otherwise specified.

The Board would like to provide the following additional information regarding the grant of the Share Options.

Vesting period: The 5,000,000 Share Options granted to Ms. Chui shall vest in Ms. Chui in the following manner:

- (i) 33.33% (1,665,000 Share Options) shall vest on 6 January 2024;
- (ii) 33.33% (1,665,000 Share Options) shall vest on 6 January 2025; and
- (iii) 33.34% (1,670,000 Share Options) shall vest on 6 January 2026.

The view of the
Remuneration
Committee:

The purpose of the share option scheme adopted by the Company on 29 May 2014 (the “**Share Option Scheme**”) is, *inter alia*, to enable the Company to grant share options to the eligible participants as incentives for their contribution to the Group and to enable the Group to attract human resources that are valuable to the Group.

In considering the grant of the Share Options to Ms. Chui, the remuneration committee of the Company (the “**Remuneration Committee**”) has taken into account the following factors: (i) Ms. Chui’s ability to contribute to the overall operations, development and long-term growth of the Group with reference to her background and management experience in the pharmaceutical industry, and her role as an executive Director of the Company; (ii) the exercise price of the Share Options represents certain premium over the market price of the Shares preceding and on the Date of Grant; and (iii) the Share Options will only be vested in three tranches from January 2024 to January 2026.

Based on the above, the Remuneration Committee is of the view that (a) the grant of the Share Options to Ms. Chui could align the interests of Ms. Chui with that of the Company and the Shareholders, and could reinforce her commitment to devote to the growth and development of the Group, which is in line with the purpose of the Share Option Scheme; and (b) it is not necessary to set performance targets and/or clawback mechanism for the grant of the Share Options to Ms. Chui.

Save as disclosed above, all other information as set out in the Announcement remains unchanged and shall continue to be valid for all purposes. This announcement is supplemental to and should be read in conjunction with the Announcement.

By order of the Board
China Biotech Services Holdings Limited
Liu Xiaolin
Chairman and Executive Director

Hong Kong, 10 January 2023

As at the date of this announcement, the Board comprises four executive Directors, namely, Mr. Liu Xiaolin (Chairman), Mr. He Xun, Mr. Huang Song and Ms. Chui Hoi Yam; and three independent non-executive Directors, namely, Mr. Yan Guoxiang, Dr. Ho Ivan Chun Kit and Mr. Qian Hongji.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk for at least 7 days from the date of its publication and on the website of the Company at www.cbshhk.com.